RecruitingPhase 4NCT05307731

Fingolimod for Type 2 Diabetes Mellitus

Fingolimod for Type 2 Diabetes Mellitus: a Pilot, Prospective, Randomized, and Open Label Single-center Study


Sponsor

General Hospital of Shenyang Military Region

Enrollment

40 participants

Start Date

Mar 15, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether fingolimod — a drug already used for multiple sclerosis — can help control blood sugar in people with type 2 diabetes. Researchers believe it may improve how the body responds to insulin. **You may be eligible if...** - You are between 18 and 70 years old - You have been clinically diagnosed with type 2 diabetes - Your HbA1c (a 3-month blood sugar average) is between 6.5% and 9.5% - You are either not on diabetes medication, or on just one oral diabetes pill with a stable dose for the past 3 months - Your BMI is 45 or below **You may NOT be eligible if...** - You have type 1 diabetes - You have had serious diabetic complications such as diabetic ketoacidosis - You have significant liver or kidney problems - You have had a heart attack, stroke, or heart failure in the past 6 months - You have certain heart rhythm problems or are on specific heart medications - You have an active infection - You are currently in another clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFingolimod

0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM

DRUGguideline-based treatment for DM

guideline-based treatment for DM


Locations(1)

Department of Neurology, General Hospital of Northern Theater Command

Shenyang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05307731


Related Trials